This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Sequenom CEO Presents At 30th Annual J.P. Morgan Healthcare Conference (Transcript)

Sequenom, Inc. ( SQNM)

30th Annual J.P. Morgan Healthcare Conference

January 12, 2012, 10:30 a.m. ET

Executi ve

Harry Hixson Jr. - Chairman and CEO


Unidentified Analyst

All right. We’re going to go ahead and get started. Welcome to day four of the J.P. Morgan Healthcare Conference. This morning we have Sequenom and Dr. Harry Hixson, who is Chairman and CEO. Please silent your cell phones and the breakout will be in the Olympic Room.

Harry Hixson Jr.

Thank you, Allen. And thanks very much to J.P. Morgan for inviting us to present here at this the most important healthcare conference of the year. I’m also very pleased to be able to treat you today and to tell you about the outstanding year that Sequenom team had in 2011, and little bit of our plans going forward for 2012 and beyond.

I’d like to remind you that we are going to be making some forward-looking statements and you should carefully read this safe harbor statement as well.

Sequenom is composed of two operating segments, the first is our original genetic analysis business, we sell a MALDI-TOF mass spectrometer, consumable reagents and research use only panels for translational medicine OncoCarta and ADME panel for drug development. The other segment is molecular diagnostics business, which is centered in our Sequenom Center for Molecular Medicine.

I’m very pleased to report that for 2011 our revenues were up approximately 23% over 2010, just to remind you that those are preliminary and unaudited numbers. We are very pleased that in the very adverse environment in 2011 that our genetic analysis business should a 6% growth in revenue for the year and actually each quarter during the year, we were better than the same quarter in the previous year.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs